60 results about "Behavioural disorders" patented technology

Aspects of the disclosure are directed to objective diagnosis of neurobehavioral disorders. In accordance with one aspect, the disclosure includes performing a spectral analysis on a Laplacian formatted electroencephalograph (EEG) data to generate a spectral coherence data; performing a plurality of regression analysis on the spectral coherence data to generate a smoothed spectral coherence data; performing a principal component analysis (PCA) on the smoothed spectral coherence data to generate an orthogonalized spectral coherence data; and performing a multivariate discriminant function analysis (DFA) on the orthogonalized spectral coherence data to generate a plurality of diagnostic rules and a diagnosis.

The inventors provide strong evidence that FGFR3 gain of function mutation expressed in the brain induces cognitive and behavior deficit. To provide evidence that the constitutive activation of FGFR3 and its downstream signalling pathways are responsible for these behavioral impairments, the inventors treated the Fgfr3A385E / + mice using subcutaneous injection of catechin isomers for at least seven days. In addition the inventors treated the Fgfr3N534K / + mice with bottle treatments. The treatment rescues the anomalies in short-term learning and in coping strategy. The present invention thus relates to a method of treating a FGFR3-related cognitive deficit in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one catechin.

The invention belongs to the technical field of traditional Chinese medicine compound preparations, and particularly relates to a qi-regulating, phlegm-reducing and nerve-calming paste, a preparation method thereof and application of the paste in preparation of a medicine for treating Parkinson's disease combined with rapid eye movement sleep behavior disorder. The paste is prepared from the following raw materials in parts by weight: 9-30 parts of semen ziziphi spinosae, 15-30 parts of Chinese yam, 10-15 parts of poria with hostwood, 9-30 parts of semen coicis, 3-10 parts of pericarpium citri reticulatae, 3-10 parts of fingered citron, 10-20 parts of sesame, 10-20 parts of rock candy and 3-5 parts of maltose. By nourishing the heart and strengthening the spleen to consolidate the root, regulating qi and reducing phlegm to relieve stagnation and tranquilizing and sedating the physique to return to the soul, the three methods are combined to achieve the purposes of tonifying without stagnation, eliminating without injury, recovering the heart and the spleen, smoothing phlegm and qi and self-hiding the soul.

The invention provides a vision detection method, device and equipment and a medium. The method comprises the following steps: acquiring a bio-electricity signal set of a detection object; inputting the bio-electricity signal set into a vision detection model to obtain a detection result set corresponding to the bio-electricity signal set; based on each detection result, determining a target vision detection identifier from a vision detection identifier set; and determining the target vision level of the detection object according to the target detection identifier. Vision detection is carried out by collecting the bio-electricity signal set of the detection object, and the behavior of the detection object does not need to be used as feedback of vision detection, so that the vision detection of people with behavior disorder has feasibility. Besides, through the corresponding form of the vision detection identifier set and the bio-electricity signal set, a more comprehensive vision detection result can be obtained, so that the vision detection result of the user is more accurate.

The invention discloses a method for improving autism behaviors through Npas4 expression and overexpression in a cat chat syndrome model, and belongs to the technical field of animal model construction. Selecting SD wild rats and CdCS model rats, and normally feeding and breeding the rats; the method comprises the following steps: measuring the protein concentration by adopting a BCA method, then carrying out Western Blot, then carrying out brain stereotactic injection, and finally carrying out behavioral testing. According to the invention, a CdCS rat model is established by using a CRISPR-Cas9 technology, and the model shows cognitive and social behavior disorders and medial prefrontal cortex (mPFC) neuron dendritic abnormality; in addition, an abnormally expressed gene is found in the model mouse, the research focuses on Npas4, and a new insight is possibly provided for disease treatment.

The present invention relates to a peptide mixture, a method for obtaining a hydrolysate, and the hydrolysate obtained using this method. The invention also relates to the use of the peptide mixture and the hydrolysate as additives in animal feed to improve growth and / or increase physical performance and / or prevent and / or treat stress and / or behavioural disorders.

The invention discloses a method for constructing a social anomaly mouse model, relates to the technical field of animal model construction, and constructs a social anomaly model of a filial generation mouse by performing bisphenol S exposure on a female mouse in a pregnancy and nursing period. According to the mouse model constructed by the invention, in the pregnancy and nursing period, BPS is exposed, and the development of left secondary motor cortex neurons is damaged, so that progeny is induced to have social behavior disorder; the activity of neurons in the left M2 brain region is activated, so that social behavior disorders can be effectively relieved. The invention not only clarifies the neural development mechanism of the environmental endocrine disrupter-induced autism-like social disorder, but also provides a new thought of activating left M2 neurons as a potential intervention means, and can be used for developing drugs for treating the social behavior disorder induced by the environmental endocrine disrupter; the invention provides a new direction for etiological research and treatment strategy exploration of neurodevelopment disorder diseases taking social defects as core symptoms, and is beneficial to promoting deep development of related medical research.

The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention and / or treatment of cognitive and / or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.

The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.

The invention relates to an application of a substance for detecting high signals of dorsal-lateral nigra in preparation of a product for detecting alpha-synucleinopathies. The Parkinson's disease and rapid eye movement sleep behavior disorder diagnosis system is constructed based on an analysis strategy of magnetic sensitive weighted imaging, the diagnosis system can be effectively applied to auxiliary diagnosis, the diagnosis sensitivity of the Parkinson's disease is 93.8%, the specificity is 96.7%, the diagnosis sensitivity of the rapid eye movement sleep behavior disorder is 66.7%, and the diagnosis sensitivity of the rapid eye movement sleep behavior disorder is 96.7%. The kit has the advantages that the sensitivity is high, the specificity is 98.0%, the rapid eye movement sleep behavior disorder or the Parkinson's disease can be subjected to etiological typing, systematic management and effective prevention of patients are facilitated, the clinical diagnosis uncertainty of the Parkinson's disease is remarkably reduced through the diagnosis mode, early screening diagnosis is promoted, and the clinical diagnosis and treatment level is improved.

This invention belongs to the field of medicinal chemistry and discloses a compound and its use. The compound, represented by Formula I, or its stereoisomers, provided herein can effectively alleviate behavioral disturbances exhibited in a rat model of autism induced by valproic acid, providing a potential candidate for the development of novel autism treatments.

The invention relates to the technical field of drug-loaded particles, in particular to a drug-loaded nanoparticle and metal polyphenol network mediated food-borne assembly, which is characterized in that natural sulfide is coated in calcium carbonate containing a mesoporous structure to form the drug-loaded nanoparticle; the preparation method comprises the following steps: preparing drug-loaded nanoparticles, and coating the outer layers of the drug-loaded nanoparticles with a nano coating with a metal-polyphenol network structure to obtain a metal polyphenol network mediated food-borne assembly which is used for preparing a drug for treating alcohol injury, and the drug is beneficial to relieving tissue injury and behavior disorder caused by alcohol.

The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a medicinal use thereof, and a method for preparing the same. The novel compounds according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; endocrinopathy; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, or chromosomal aberration.

According to one embodiment disclosed herein, a composition for preventing or treating mental diseases or behavioral disorders in animals may include a selective serotonin reuptake inhibitor (SSRI) and a serotonin antagonist-reuptake inhibitor (SARI). The representative figure may be figure 3. The representative figure may be figure 3.

The application discloses a set of biomarkers for diagnosing Parkinson disease with rapid eye movement sleep behavior disorder and application thereof, and belongs to the technical field of biomarkers. The application studies changes in plasma metabolite levels of patients with Parkinson disease with rapid eye movement sleep behavior disorder (PD+RBD) and changes in inflammation-related proteins based on metabolomics and protein analysis methods, finds potential biomarkers, and can be applied to the diagnosis of PD+RBD, solves the current problem of diagnosing Parkinson disease with rapid eye movement sleep behavior disorder in the clinic, helps to establish a scientific treatment plan as early as possible, relieves the pain of patients, and has a very good application prospect.

The invention relates to a pharmaceutical composition for treating diseases induced by sleep deprivation and application of the pharmaceutical composition, and belongs to the technical field of medicines.The pharmaceutical composition is prepared from 5-60 parts of honey-fried licorice roots, 5-35 parts of dried ginger, 5-35 parts of radix paeoniae alba, 5-35 parts of cinnamon, 5-35 parts of panax notoginseng and 2-12 parts of leeches. The pharmaceutical composition disclosed by the invention can be used for effectively treating or improving diseases such as neuroinflammation, cognitive behavior disorder, blood-brain barrier injury, intestinal leakage and the like induced by sleep deprivation, and these effects prove that the pharmaceutical composition disclosed by the invention can be used for effectively treating or relieving related diseases induced by sleep deprivation.

This invention provides a treatment for patients with developmental and epileptic encephalopathy (DEE) that addresses behavioral problems in addition to seizures, without causing undesirable side effects such as somnolence, lethargy, withdrawal, and sedation. [Solution] A method is provided for treating behavioral problems and seizures in a subject having DEE, comprising administering an effective amount of cannabidiol (CBD) transdermally to the subject, wherein the behavioral problems are treated in the subject.

Detection of fast eye movement (REM) sleep and associated abnormalities is important for identifying various nervous system diseases. The present disclosure relates to the detection of time intervals during which a subject is in REM sleep by utilizing electroencephalogram (EEG) data from selective spectral frequencies. The techniques as disclosed herein may use one or more EEG electrodes, and more particularly, single channel EEG signals provide a simple and cost-effective solution. The disclosed techniques may pre-process the EEG data, extract features and / or derived features for one or more time intervals from selective spectral bands (e.g., delta and gamma). These extracted features may be normalized and clustered to further determine REM, non-REM, and waking time intervals. By using one or more non-EEG sensors to detect the presence of muscular tension of the identified REM sleep intervals, and by performing sleep pattern analysis, potential REM intervals can be verified to detect REM behavioral disorders.

The present invention relates to compositions for use in the treatment, management or amelioration of FMRI mediated autism and Fragile X Syndrome (FXS), wherein the composition comprises one or more non-nucleoside reverse transcriptase inhibitors (NNRTIs). The invention also relates to one or more NNRTIs for use as medicaments for treating a range of autistic diseases, diseases having an autistic component and behavioural disorders.

The invention discloses a primer probe composition and application thereof. The primer probe composition disclosed by the invention comprises a forward primer, a reverse primer and a probe, the nucleotide sequence of the forward primer is as shown in SEQ ID NO.1, the nucleotide sequence of the reverse primer is as shown in SEQ ID NO.2, and the nucleotide sequence of the probe is as shown in SEQ ID NO.3. When the primer probe composition is used for testing clinical samples, normal and rapid eye movement sleep behavior disorder patient samples can be well distinguished, and whether the rapid eye movement sleep behavior disorder patient can be converted into Parkinson's disease or not in the later period can be evaluated.

This invention discloses the application of bimatoprost in the preparation of drugs for the prevention and / or treatment of Parkinson's disease, within the field of drug reuse. Bimatoprost is a prostaglandin F2α analog, currently mainly used for glaucoma and eyelash growth. This invention has found that bimatoprost can improve Parkinson's disease-related behavioral disorders, increase the expression of tyrosine hydroxylase, a protein associated with dopaminergic neurons in the substantia nigra, and reduce the abnormal accumulation of α-synuclein, thus exhibiting good ameliorative and protective effects against Parkinson's disease. This invention provides a new drug option for the treatment of Parkinson's disease.

Disclosed are pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and a therapeutically active ingredient of donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt thereof. Also disclosed are methods of using the pharmaceutical compositions to treat patients with mental disorders, behavioral disorders, cognitive disorders.

To provide new uses of a 5-HT4 receptor agonist, specifically isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy / indifference, agitation, aggression, depression, anxiety, irritability / lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation / euphoria, psychosis, disinhibition, sleep and night time behavior disorders, or appetite and eating disorders, and use of the compounds in the manufacture of medicament intended for the treatment of the disorders described herein.SOLUTION: The 5-HT4 receptor agonist of the present invention can be a potent drug candidate for treatment of menopause-related memory and cognitive loss.SELECTED DRAWING: None

To provide methods for diagnosing and treating conduct disorder.SOLUTION: Diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes, and the treatment is performed with nonselective activators of mGluRs such as fasoracetam.SELECTED DRAWING: None

The present invention provides pharmaceutical composition for the treatment of tauopathy-related diseases that can significantly improve cognitive and behavioral impairments by reducing neuronal uptake and propagation of disease-associated tau.

The present invention provides a composition containing, as an active ingredient, a ginseng extract selected from the group consisting of ginseng extract, red ginseng extract, and black ginseng extract. When the composition according to the present invention is administered in combination with a steroid drug, it has the effect of improving or suppressing side effects caused by the steroid drug, such as weakened immunity and increased risk of infection, steroid-induced diabetes, osteoporosis, increased blood pressure and electrolyte abnormalities, changes in body shape, myopathy, osteonecrosis, cataracts, skin changes, and behavioral disorders.

The invention discloses a mild behavioral disorder cognitive decline prediction method based on multi-modal image fusion, and relates to the technical field of mild cognitive impairment prediction. According to the method, feature vectors of different modes are spliced to form a joint feature matrix, redundant information is eliminated through principal component analysis, and main variation components are reserved; inputting the feature set after dimension reduction into a prediction model based on machine learning, optimizing hyper-parameters through cross validation, and training a classifier so as to identify a cognitive decline risk mode of the patient with the mild behavioral disorder; multi-modal image data are received in real time through a standardized API interface, a prediction algorithm is automatically executed, and a report including individualized risk scores, confidence intervals, risk level classification and interpretability analysis is generated; the report is output in a structured format, so that a clinician can quickly refer to the report in the diagnosis process, meanwhile, the report is supported to be exported in a PDF or electronic health record format, and seamless integration with an existing medical information system is ensured.

Pyridazine based compounds and pharmaceutical compositions that may be used for treating synaptic and behavioral dysfunction such as that associated with Alzheimer's Disease, tauopathies, Alzheimer's Disease related dementia, and other dementia. Compounds disclosed herein can be used for treatment of neuropsychiatric, cognitive or behavioral disorders, especially those associated with neurodegenerative disorders. Also disclosed is a method for treating neuropsychiatric, cognitive or behavioral disorders in a subject suffering from a neurodegenerative disease by administering these compounds and pharmaceutical compositions to a subject in need thereof.

The invention provides a Parkinson's disease genetic polymorphism-based quick-moving eye sleep behavior disorder gene screening method and application. The screening method comprises the following steps: extracting genome DNA from peripheral blood mononuclear cells of all idiopathic rapid eye movement sleep behavior disorder iRBD subjects; the method comprises the following steps: querying PD related genes and single nucleotide polymorphism (SNP) through a PPMI database, preparing a target gene Panel, and carrying out clustering analysis on all target genes; carrying out high-throughput sequencing on the SNP by using the target gene Panel; carrying out genetic typing on the SNP; estimating the disease risk of each SNP and iRBD by using logistic regression analysis; and drawing an ROC curve to analyze the diagnosis effect of the SNP in the rapid eye movement sleep behavior disorder. The specific SNP related to the iRBD risk is identified, and then the diagnosis effect evaluation of the ROC curve is combined, so that the hidden iRBD patients can be identified more accurately, conveniently and efficiently.

The invention relates to a traditional Chinese medicine composition for treating child cerebral palsy as well as a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition for treating child cerebral palsy comprises the following raw materials in parts by weight: 30-56 parts of aspidopterys obcordata, 25-40 parts of ornithogalum caudatum, 10-18 parts of angelica sinensis, 8-15 parts of mangnolia officinalis and the like. The traditional Chinese medicine composition for treating child cerebral palsy is prepared by taking aspidopterys obcordata and ornithogalum caudatum in a proper proportion as monarch drugs and taking a proper amount of angelica sinensis, mangnolia officinalis, lycopodium clavatum, gordon euryale seed and liquorice as auxiliary materials and combining all the drugs. Animal experiments show that the traditional Chinese medicine composition can relieve symptoms such as low muscle strength and behavior disorder of an animal model of a rat suffering from hypoxia and ischemia cerebral palsy, provides a new and potential clinical treatment means for treating children cerebral palsy, and has wide application and significance.